| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/MCNE.2000.0914 |
| P8608 | Fatcat ID | release_ilcgnk5q7vgetn5po3cxv2z2a4 |
| P698 | PubMed publication ID | 11124893 |
| P2093 | author name string | Wilkin GP | |
| Knott C | |||
| Stern G | |||
| P433 | issue | 6 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 724-739 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Molecular and Cellular Neuroscience | Q6895985 |
| P1476 | title | Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. | |
| P478 | volume | 16 |
| Q41916170 | 2-cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone inhibits LPS-induced BV2 microglial activation through MAPK/NF-kB signaling pathways |
| Q36129283 | A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease |
| Q37407288 | A phenotypic model recapitulating the neuropathology of Parkinson's disease |
| Q42098321 | A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease. |
| Q43956391 | APP knockout attenuates microglial activation and enhances neuron survival in substantia nigra compacta after axotomy |
| Q44241668 | Activation of constitutive nitric oxide synthase(s) and absence of inducible isoform in aged rat brain |
| Q38218083 | Advances in non-dopaminergic treatments for Parkinson's disease |
| Q48171351 | An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. |
| Q35046915 | An inflammatory review of Parkinson's disease. |
| Q64243589 | Annexin A1 as Neuroprotective Determinant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-Ischemic Encephalopathy |
| Q37101343 | Annexin A1 translocates to nucleus and promotes the expression of pro-inflammatory cytokines in a PKC-dependent manner after OGD/R. |
| Q35132315 | Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. |
| Q60684589 | Annexin III implicated in the microglial response to motor nerve injury |
| Q51963520 | Annexin-1 is abnormally expressed in fragile X syndrome: two-dimensional electrophoresis study in lymphocytes. |
| Q39412033 | Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model. |
| Q90261019 | Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model |
| Q38935503 | Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats |
| Q35118654 | Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection |
| Q92929332 | Antioxidant and Anti-inflammatory Mechanisms of Neuroprotection by Ursolic Acid: Addressing Brain Injury, Cerebral Ischemia, Cognition Deficit, Anxiety, and Depression |
| Q46141134 | Antiulcerogenic and anti-inflammatory activities of the essential oil from Pterodon emarginatus seeds. |
| Q64761573 | Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients |
| Q34994982 | Attenuation of inflammatory-mediated neurotoxicity by Saururus chinensis extract in LPS-induced BV-2 microglia cells via regulation of NF-κB signaling and anti-oxidant properties |
| Q43270658 | Augmenting Endogenous Levels of Retinal Annexin A1 Suppresses Uveitis in Mice |
| Q49433973 | Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor |
| Q35013972 | Blocking NO synthesis: how, where and why? |
| Q38028894 | COX-2 in the neurodegenerative process of Parkinson's disease |
| Q44619649 | COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice |
| Q26849232 | Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease |
| Q44574607 | Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice |
| Q54250937 | Curcumenol isolated from Curcuma zedoaria suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. |
| Q51058898 | Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection. |
| Q48771886 | Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model |
| Q33836942 | Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration |
| Q35903755 | Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases |
| Q36847262 | Death in the substantia nigra: a motor tragedy |
| Q80995710 | Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex |
| Q38295210 | Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings |
| Q28550579 | Effects of Ranolazine on Astrocytes and Neurons in Primary Culture |
| Q36882447 | Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease |
| Q35585752 | Effects of paeonol on anti-neuroinflammatory responses in microglial cells |
| Q47397177 | Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra |
| Q37133410 | Emerging role of glial cells in the control of body weight |
| Q34298569 | EnrichNet: network-based gene set enrichment analysis. |
| Q34784469 | Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases |
| Q42523538 | Expression of inducible nitric oxide synthase and cyclooxygenase-2 after excitotoxic damage to the immature rat brain |
| Q35014520 | Expression of mutant alpha-synuclein modulates microglial phenotype in vitro |
| Q37322767 | Folic Acid Is Able to Polarize the Inflammatory Response in LPS Activated Microglia by Regulating Multiple Signaling Pathways |
| Q26779933 | Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases |
| Q48793100 | Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice |
| Q34077007 | Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity. |
| Q35022594 | Glial cell response: A pathogenic factor in Parkinson's disease. |
| Q30991616 | Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants |
| Q53354190 | Glutathione S-transferase P1 suppresses iNOS protein stability in RAW264.7 macrophage-like cells after LPS stimulation. |
| Q93357641 | Immune system responses in Parkinson's disease: Early and dynamic |
| Q45104172 | Immunohistochemistry of neuronal nitric oxide synthase and protein nitration in the striatum of the aged rat. |
| Q28079187 | Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease |
| Q40724973 | Impact of endogenous nitric oxide on microglial cell energy metabolism and labile iron pool |
| Q26782894 | Implications of glial nitric oxide in neurodegenerative diseases |
| Q35274780 | Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia |
| Q44464140 | Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. |
| Q47786283 | Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons. |
| Q36052641 | Inflammation as a causative factor in the aetiology of Parkinson's disease |
| Q41917715 | Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease |
| Q35170207 | Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria |
| Q26795984 | Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies |
| Q48281442 | Intermittent ethanol exposure induces inflammatory brain damage and causes long-term behavioural alterations in adolescent rats. |
| Q37217248 | Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice |
| Q35545545 | Intrinsic regulation of brain inflammatory responses. |
| Q43068283 | Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation? |
| Q35909522 | Ionizing Radiation Induces Altered Neuronal Differentiation by mGluR1 through PI3K-STAT3 Signaling in C17.2 Mouse Neural Stem-Like Cells |
| Q64273411 | Kaempferol Attenuates LPS-Induced Striatum Injury in Mice Involving Anti-Neuroinflammation, Maintaining BBB Integrity, and Down-Regulating the HMGB1/TLR4 Pathway |
| Q35376097 | Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cells |
| Q36285084 | L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease |
| Q48267087 | Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death |
| Q42941876 | Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence |
| Q38055706 | Long-term effects of ionising radiation on the brain: cause for concern? |
| Q40625594 | Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease |
| Q92618301 | Methylmercury Neurotoxicity: Exploring Potential Novel Targets |
| Q37655232 | Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory process |
| Q58799080 | Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention |
| Q92882814 | Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease |
| Q37794379 | Microglial activation and chronic neurodegeneration |
| Q38815779 | Microglial phenotypes in Parkinson's disease and animal models of the disease |
| Q37796012 | Modeling neuroinflammatory pathogenesis of Parkinson’s disease |
| Q36616362 | Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease |
| Q38887346 | Molecular changes in the postmortem parkinsonian brain |
| Q40778644 | Mutant alpha-synuclein overexpression mediates early proinflammatory activity |
| Q58695107 | NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease |
| Q37974560 | NSAIDs in the treatment and/or prevention of neurological disorders |
| Q27027973 | Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity |
| Q29616300 | Neuroinflammation in Parkinson's disease: a target for neuroprotection? |
| Q37677181 | Neuroinflammation in the living brain of Parkinson's disease |
| Q42908536 | Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease |
| Q39341263 | Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease |
| Q48566307 | Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. |
| Q46537044 | Neuroprotective and anti-inflammatory effects of morin in a murine model of Parkinson's disease |
| Q35632000 | Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease |
| Q36109494 | Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone |
| Q33499111 | Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease |
| Q50910086 | Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. |
| Q44208206 | Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes |
| Q48568146 | Nitric oxide-producing microglia mediate thrombin-induced degeneration of dopaminergic neurons in rat midbrain slice culture |
| Q28195213 | Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats |
| Q36607332 | Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation |
| Q64242771 | Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease |
| Q28275946 | Oxidative stress in neurodegeneration: cause or consequence? |
| Q59340795 | P38 Mitogen-activated Protein Kinase and Parkinson's Disease |
| Q78747091 | Parkinson's disease |
| Q28084395 | Parkinson's disease as a result of aging |
| Q33874635 | Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research |
| Q35489240 | Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. |
| Q36860620 | Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes |
| Q46736932 | Pathological dynamics of activated microglia following medial forebrain bundle transection |
| Q37878282 | Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. |
| Q37699935 | Peripheral leukocyte apoptosis in patients with Parkinsonism: correlation with clinical characteristics and neuroimaging findings |
| Q35971342 | Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease. |
| Q91706849 | Pharmacological Targeting of Microglial Activation: New Therapeutic Approach |
| Q36478649 | Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt |
| Q30573637 | Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease |
| Q37812676 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases |
| Q36403694 | Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase |
| Q47613121 | Radio Electric Asymmetric Conveyer Technology Modulates Neuroinflammation in a Mouse Model of Neurodegeneration. |
| Q35942562 | Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease |
| Q36376140 | Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration |
| Q35050412 | Regulation of microglia - potential new drug targets in the CNS. |
| Q38980358 | Regulatory effects of fisetin on microglial activation. |
| Q44597471 | Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress |
| Q53391751 | Relevance of COX-2 gene expression in dementia with lewy bodies associated with Alzheimer pathology. |
| Q37707773 | Rho kinase II interference by small hairpin RNA ameliorates 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine‑induced parkinsonism in mice |
| Q34014053 | Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases |
| Q37139465 | Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols |
| Q26863534 | Role of prostaglandins in neuroinflammatory and neurodegenerative diseases |
| Q35949729 | Role of vitamin d in Parkinson's disease |
| Q36411027 | S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway |
| Q24794457 | Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease |
| Q35673658 | Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B. |
| Q28475466 | Striatal neuroinflammation promotes Parkinsonism in rats |
| Q37198492 | Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nitric-oxide synthase 2 expression in astrocytes by a novel diindolylmethane analog protects striatal neurons against apoptosis |
| Q40126232 | Synuclein activates microglia in a model of Parkinson's disease |
| Q41616792 | Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra |
| Q47338105 | The Anti-inflammatory Effects of 4-((5-Bromo-3-chloro-2-hydroxybenzyl) amino)-2-hydroxybenzoic Acid in Lipopolysaccharide-Activated Primary Microglial Cells |
| Q39429761 | The Effect of Osteopontin on Microglia. |
| Q35577679 | The Hunt for a Cure for Parkinson’s Disease |
| Q36429576 | The Role and Effects of ANXA1 in Temporal Lobe Epilepsy: A Protection Mechanism? |
| Q39427395 | The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide |
| Q64865100 | The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6. |
| Q38242194 | The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging |
| Q38198015 | The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders |
| Q35224286 | The morphological and molecular changes of brain cells exposed to direct current electric field stimulation. |
| Q27687514 | The restorative role of annexin A1 at the blood-brain barrier. |
| Q38105903 | The role of inflammation in sporadic and familial Parkinson's disease |
| Q38860761 | The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration |
| Q26861263 | The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? |
| Q38108496 | The role of β-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms |
| Q42170364 | Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. |
| Q54752771 | Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. |
| Q37481073 | Tollip, an early regulator of the acute inflammatory response in the substantia nigra |
| Q34768987 | Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra |
| Q64779062 | Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism |
| Q39009678 | Translocator protein 18 kDa negatively regulates inflammation in microglia |
| Q36136789 | Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation |
| Q40330344 | Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase |
| Q37809751 | Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease |
| Q36052832 | YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. |
| Q37070916 | alpha-Synuclein: a therapeutic target for Parkinson's disease? |
| Q39012371 | l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? |
| Q38951947 | l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? |
| Q42783371 | α-Synuclein Alters Toll-Like Receptor Expression |
Search more.